Suzhou Ribo Life Science recently inked a deal with Qilu Pharmaceutical, granting them rights to develop, produce, and market PCSK9 inhibitor drug RBD7022 (SR043) in Greater China.

PCSK9 inhibitors lower circulating LDL-C levels by blocking the degradation of LDL-R by PCSK9.

On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment of head and neck squamous cell cancer (HNSCC) was reported in 2023 ESMO_ASIA.

The SPC extends patent protection up to 5 years to offset delays in regulatory approval.

On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.

Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.

Travere Therapeutics has begun a critical Phase 3 study of Pegtibatinase in the management of Classical Homocystinuria (HCU).

The fractional dose comes from the same full dose vaccine. It has been given to millions of people to prevent yellow fever in the past.

Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3-mediated NRG1 signaling in NRG1+ cancer.

In the European Union (EU), Compassionate use is a treatment option that allows the use of an unauthorised medicine.

Rezolute has commenced a pivotal Phase 3 clinical trial for its investigative drug, RZ358, aimed at treating patients with Congenital Hyperinsulinism.

Here are the open status categories for FDA postmarketing requirements and commitments listed.